BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22085375)

  • 1. Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
    Tokuda Y; Takigawa N; Kozuki T; Kamei H; Bessho A; Tada A; Hotta K; Katsui K; Kanazawa S; Tanimoto M; Kiura K
    Acta Oncol; 2012 Apr; 51(4):537-40. PubMed ID: 22085375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
    Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemoradiation therapy with docetaxel/cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small-cell lung cancer: results of a phase I study.
    Huber RM; Borgmeier A; Flentje M; Willner J; Schmidt M; Manegold C; Bramlage P; Debus J
    Clin Lung Cancer; 2010 Jan; 11(1):45-50. PubMed ID: 20085867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
    Harada H; Nishio M; Murakami H; Ohyanagi F; Kozuka T; Ishikura S; Naito T; Kaira K; Takahashi T; Horiike A; Nishimura T; Yamamoto N
    Clin Lung Cancer; 2013 Jul; 14(4):440-5. PubMed ID: 23540866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
    Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.
    Langer CJ; Curran WJ; Keller SM; Catalano RB; Litwin S; Blankstein KB; Haas N; Campli SN; Comis RL
    Cancer J Sci Am; 1996; 2(2):99-105. PubMed ID: 9166507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
    Weitberg AB; Liu L; Yashar J; Glicksman AS
    J Exp Clin Cancer Res; 2001 Sep; 20(3):335-40. PubMed ID: 11718211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
    Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
    Gandara DR; Chansky K; Albain KS; Leigh BR; Gaspar LE; Lara PN; Burris H; Gumerlock P; Kuebler JP; Bearden JD; Crowley J; Livingston R;
    J Clin Oncol; 2003 May; 21(10):2004-10. PubMed ID: 12743155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
    Descourt R; Vergnenegre A; Barlesi F; Lena H; Fournel P; Falchero L; Berard H; Hureaux J; Le Caer H; Chavaillon JM; Geriniere L; Monnet I; Chouabe S; Robinet G;
    J Thorac Oncol; 2011 Feb; 6(2):351-7. PubMed ID: 21164367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
    Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
    Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
    Saitoh J; Saito Y; Kazumoto T; Kudo S; Yoshida D; Ichikawa A; Sakai H; Kurimoto F; Kato S; Shibuya K
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1791-6. PubMed ID: 21601375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trial.
    Poudenx M; Bondiau PY; Chamorey E; Venissac N; Otto J; Pourel N; Castelnau O; Tessier E; De Surmont Salasc B; Berdah JF; Pop D; Michel C; Mouroux J
    Oncology; 2012; 83(6):321-8. PubMed ID: 22986621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.